Novartis Says Net Sales Is Expected To Grow 5% (At Constant Currency) CAGR 2023-2028 With Core Operating Income Margin Expanding To ~40%+ By 2027
Portfolio Pulse from Benzinga Newsdesk
Novartis projects a 5% compound annual growth rate (CAGR) in net sales from 2023 to 2028 at constant currency. The company also anticipates its core operating income margin to expand to over 40% by 2027.
January 31, 2024 | 8:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis expects a 5% CAGR in net sales from 2023 to 2028 and projects its core operating income margin to exceed 40% by 2027.
The positive growth outlook provided by Novartis, including a steady CAGR in net sales and a significant expansion in core operating income margin, is likely to be viewed favorably by investors. This could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100